5912-35-6

Basic information

• Product Name: 8-BROMO-1,7-NAPHTHYRIDIN-6-AMINE
• Synonyms: 8-BROMO-1,7-NAPHTHYRIDIN-6-AMINE;6-Amino-8-bromo-1,7-naphthyridine;8-broMo-[1,7]naphthyridin-6-ylaMine
• CAS NO: 5912-35-6
• Molecular Formula: C₈H₆BrN₃
• Molecular Weight: 224.07
• Mol File: 5912-35-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 181 °C
• Boiling Point: 407.187°C at 760 mmHg
• Flash Point: 200.06°C
• Appearance: /
• Density: 1.744g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.747
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.92±0.30(Predicted)
• CAS DataBase Reference: 8-BROMO-1,7-NAPHTHYRIDIN-6-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-1,7-NAPHTHYRIDIN-6-AMINE(5912-35-6)
• EPA Substance Registry System: 8-BROMO-1,7-NAPHTHYRIDIN-6-AMINE(5912-35-6)

Safety Data

• Hazardous Substances Data: 5912-35-6(Hazardous Substances Data)

Usage

General Description

8-Bromo-1,7-naphthyridin-6-amine is a chemical compound with the molecular formula C8H6BrN3. It is a derivative of naphthyridine, a fused heterocyclic compound containing a pyridine ring fused to a pyrimidine ring. 8-Bromo-1,7-naphthyridin-6-amine contains a bromine atom and an amine group, which makes it useful in various chemical reactions and synthesis processes. It has potential applications in pharmaceutical research and development, as well as in the production of other organic compounds. Due to its unique structure and reactivity, 8-Bromo-1,7-naphthyridin-6-amine is of interest to chemists and researchers studying heterocyclic compounds and organic synthesis.

InChI:InChI=1/C8H6BrN3/c9-8-7-5(2-1-3-11-7)4-6(10)12-8/h1-4H,(H2,10,12)

Upstream product

• 116986-13-1 2-cyano-3-(bromomethyl)pyridine 
• 20970-75-6 2-cyano-3-methylpyridine 
• 6443-85-2 3-pyridinylacetonitrile 
• 6635-88-7 3-(cyanomethyl)pyridine 1-oxide 
• 5912-34-5 2-cyano-pyridin-3-yl-acetonitrile 

Downstream Products

• 207279-13-8 8-(3-chlorophenyl)-[1,7]naphthyridin-6-ylamine 
• 207278-99-7 6-amino-8-(3-nitrophenyl)-1,7-naphthyridine 
• 207279-14-9 3-(6-amino-[1,7]naphthyridin-8-yl)benzonitrile 
• 1201843-32-4 N-(2-chloro-5-(1,7-naphthyridin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 524734-44-9 8-(3-methoxyphenyl)-1,7-naphthyridin-6-yl trifluoromethanesulfonate 
• 1295626-56-0 4-(8-ethyl-1,7-naphthyridin-6-yl)benzoic acid 
• 1295626-55-9 methyl 4-(8-ethyl-1,7-naphthyridin-6-yl)benzoate 
• 5912-36-7 1,7-naphthyridin-6-amine 
• 106309-54-0 6-amino-8-morpholino-1,7-naphthyridine 
• 713145-54-1 8-(5-fluoro-2-methoxy-phenyl)-[1,7]naphthyridin-6-ylamine 
• 713145-53-0 8-(3-fluoro-phenyl)-[1,7]naphthyridin-6-ylamine 
• 207279-23-0 NVP 
• 261960-44-5 6-trifluoromethylsulfonyloxy-8-(3-nitrophenyl)-1,7-naphthyridine 
• 207279-10-5 6-(4-carboxyphenyl)-8-(3-cyanophenyl)-1,7-naphthyridine 

Relevant articles and documents

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Compound used as EGFR kinase inhibitor and application thereof

The invention relates to a compound used as an EGFR kinase inhibitor and application thereof, the compound has a structure as shown in a formula I, and the compound can be used for adjusting EGFR kinase activity or treating related diseases, especially non-small cell lung cancer.

Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate

The solubility-driven optimization of a series of 1,7-napthyridine phosphodiesterase-4 inhibitors is described. Directed structural changes resulted in increased aqueous solubility, enabling superior pharmacokinetic properties with retention of PDE4 inhib